Skip to contentB
BioCardia, Inc.
B
BCDABioCardia, Inc. Q2 2026 · 10-Q
Revenue—
Net Income-$1.61M-$1.61MN/M vs Q2 2025 EPS, diluted—
Operating Income-$1,623,000N/M Operating Cash Flowderived-$1,735,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioCardia, Inc. · CIK 925741 · Engraved from SEC EDGAR
Free Cash Flowderived-$1,735,000N/M ended Jun 30, 2026 · filed Aug 12, 2026 · 43 d after period end